<DOC>
	<DOCNO>NCT01083732</DOCNO>
	<brief_summary>To investigate safety tolerability dabigatran etexilate solution child obtain preliminary pharmacokinetic/pharmacodynamic data</brief_summary>
	<brief_title>Safety Tolerability Dabigatran Etexilate Solution Children 1 &lt; 12 Years Age</brief_title>
	<detailed_description>Purpose :</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1. male females 1 less 12 year age 2. objective diagnosis primary VTE 3. completion plan treatment course LMWH OAC primary VTE 4. write informed consent parent ( legal guardian ) patient assent ( applicable ) Exclusion criterion : 1. weight less 9 kg 2. condition associate increase risk bleed 3. patient condition would allow safe participation study Note : Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>